Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Status:
Completed
Trial end date:
2013-03-14
Target enrollment:
Participant gender:
Summary
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250
(^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma
(RCC). Study objectives were to determine the safety, targeting, and dosimetry of
^90Y-DOTA-cG250, using indium-111 conjugated chimeric G250 (^111In-DOTA-cG250) as a
surrogate, as well as to evaluate the immunogenicity of cG250.